Clinical Trials Browser

INDUSTRY × trastuzumab deruxtecan × Breast × Clear all

Breast Neoplasms

NCT06324357 2026-04-15

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Phase 1/2 Recruiting

768 enrolled

BreastGastrointestinal

Adenocarcinoma Of Esophagus, Breast Neoplasms, Colorectal Neoplasms

NCT05950945 2026-04-08

Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

Phase 3 Recruiting

250 enrolled

Breast

Breast Neoplasms

NCT07497386 2026-03-27

A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer

Phase 2 Not yet recruiting

150 enrolled

Breast

Unresectable Locally Recurrent Breast Cancer

NCT04539938 2026-03-23

HER2CLIMB-04

Phase 2 Completed

70 enrolled 23 charts

Breast

Breast Neoplasms

NCT03424005 2026-03-16

Morpheus-panBC

Phase 1/2 Recruiting

792 enrolled

Breast

Breast Neoplasms

NCT05417594 2026-03-12

CERTIS1

Phase 1/2 Recruiting

695 enrolled

BreastCNSGastrointestinalGenitourinaryGynecologic

Astrocytoma, Breast Neoplasms, Fallopian Tube Neoplasms, Glioma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT04494425 2026-03-04

DB-06

Phase 3 Active not recruiting

866 enrolled 25 charts 3 FDA

Breast

Breast Neoplasms

NCT03523585 2026-02-27

DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

Phase 3 Completed

608 enrolled 17 charts

Breast

Breast Neoplasms

NCT05113251 2026-02-23

Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer

Phase 3 Active not recruiting

927 enrolled

Breast

Breast Neoplasms

NCT04784715 2026-02-20

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

Phase 3 Active not recruiting

1,157 enrolled 3 FDA

Breast

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis

NCT05945732 2026-02-12

DESTINY Breast Respond HER2-low Europe

Recruiting

1,155 enrolled

Breast

Breast Neoplasms

NCT04739761 2026-02-11

DESTINY-B12

Phase 3 Active not recruiting

506 enrolled 27 charts

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT03742102 2026-02-02

BEGONIA

Phase 1/2 Active not recruiting

243 enrolled 13 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06210776 2026-01-12

A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)

Recruiting

800 enrolled

Breast

Breast Neoplasms

NCT04556773 2025-12-17

DB-08

Phase 1 Active not recruiting

138 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04538742 2025-12-08

DB-07

Phase 1/2 Active not recruiting

245 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT06429761 2025-11-24

STRIDE

Phase 4 Recruiting

100 enrolled

Breast

Breast Neoplasms

NCT04042701 2025-11-18

DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer

Phase 1 Active not recruiting

115 enrolled

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT06271837 2025-10-22

A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors

Phase 2 Recruiting

175 enrolled

Breast

Breast Neoplasms

NCT03529110 2025-10-21

DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

Phase 3 Active not recruiting

524 enrolled 11 charts 2 FDA

Breast

Breast Neoplasms

NCT06386263 2025-10-15

HER-TEMPO

Completed

22 enrolled

Breast

Breast Neoplasms

NCT03734029 2025-10-06

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

Phase 3 Active not recruiting

557 enrolled 22 charts 2 FDA

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT06727227 2025-07-01

EXPLORE

Recruiting

135 enrolled

Breast

Breast Neoplasms

NCT03248492 2025-06-26

DESTINY-Breast01

Phase 2 Terminated

253 enrolled 21 charts 2 FDA

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT06832202 2025-06-15

A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients

Phase 2 Recruiting

50 enrolled

Breast

HER2-low Hormone Receptor Positive Breast Cancer

NCT05765851 2025-05-11

A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors

Phase 1 Active not recruiting

78 enrolled

Breast

Breast Neoplasms

NCT04622319 2025-05-09

DESTINY-Breast05

Phase 3 Active not recruiting

1,600 enrolled

Breast

HER2-Positive Primary Breast Cancer

NCT06231693 2025-05-08

Trastuzumab-deruxtecan in Patients With Triple-negative Metastatic HER2-Low Breast Cancer: Real-world Experience in Brazil

Terminated

2 enrolled

Breast

Breast Neoplasms

NCT03523572 2025-01-27

Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer

Phase 1 Completed

86 enrolled 22 charts

BreastGenitourinary

Breast Neoplasms, Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT05458401 2024-03-15

EUROPA T-DXd

Completed

256 enrolled

Breast

HER2-positive Breast Cancer

NCT03368196 2022-11-03

DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein

Phase 1 Completed

12 enrolled 15 charts

BreastGastrointestinal

Adenocarcinoma, Breast Neoplasms, Neoplasms, Stomach Neoplasms

NCT05091528 2022-08-18

A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers

Phase 1/2 Terminated

2 enrolled 9 charts

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Colorectal Neoplasms

NCT03366428 2022-04-12

Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2-Expressing Breast Cancer

Phase 1 Completed

51 enrolled 14 charts

Breast

Breast Neoplasms, Neoplasms

Clinical Trials

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer

HER2CLIMB-04

Morpheus-panBC

CERTIS1

DB-06

DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

DESTINY Breast Respond HER2-low Europe

DESTINY-B12

BEGONIA

A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)

DB-08

DB-07

STRIDE

DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer

A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors

DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

HER-TEMPO

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

EXPLORE

DESTINY-Breast01

A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients

A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors

DESTINY-Breast05

Trastuzumab-deruxtecan in Patients With Triple-negative Metastatic HER2-Low Breast Cancer: Real-world Experience in Brazil

Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer

EUROPA T-DXd

DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein

A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers

Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2-Expressing Breast Cancer